CLDX Live signaler | Maksimer profitt med Getagraph.com

KJøP 115899 min ago

@ $36.11

Utstedt: 14 feb 2024 @ 19:49

Avkastning: 17.88%

Forrige signal: feb 13 - 18:40

Forrige signal: Selg

Avkastning: 0.46 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases...

Stats
Dagens volum	583 814
Gjennomsnittsvolum	934 929
Markedsverdi	2.81B
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $-0.690 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.58
ATR14	$0.0660 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-13	Jimenez Freddy A.	Buy	20 000	Common Stock
2024-02-13	Jimenez Freddy A.	Buy	4 166	Common Stock
2024-02-13	Jimenez Freddy A.	Sell	4 166	Incentive Stock Option (Right to Buy)
2024-02-13	Jimenez Freddy A.	Sell	20 000	Incentive Stock Option (Right to Buy)
2024-01-02	Martin Samuel Bates	Buy	10 750	Common Stock

INSIDER POWER
75.31
Last 97 transactions
Buy: 2 900 849 \| Sell: 507 801

Volum Korrelasjon

Lang: 0.53 (weak)

Kort: 0.71 (moderate)

Signal:(62.877) Neutral

Celldex Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
NSTS	0.918
BOKF	0.917
FNWD	0.917
GCBC	0.916
NECB	0.913
UMBF	0.913
MSBI	0.91
HMNF	0.909
AHPI	0.907
FSBC	0.906

10 Mest negative korrelasjoner
CHMA	-0.906
VTIP	-0.906
DSPG	-0.895
SUMO	-0.893
SOPH	-0.887
SMED	-0.882
OSMT	-0.878
NVCN	-0.876
MNTV	-0.876
DVCR	-0.872

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Celldex Therapeutics Inc Korrelasjon - Valuta/Råvare

-0.50
( weak negative )

-0.48
( neutral )

0.00
( neutral )

-0.42
( neutral )

-0.35
( neutral )

Celldex Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$6.88M
Bruttogevinst:	$3.88M (56.30 %)
EPS:	$-2.92

FY	2023
Omsetning:	$6.88M
Bruttogevinst:	$3.88M (56.30 %)
EPS:	$-2.92

FY	2022
Omsetning:	$2.36M
Bruttogevinst:	$957 000 (40.60 %)
EPS:	$-2.62

FY	2021
Omsetning:	$4.65M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.640

Financial Reports:

No articles found.

Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.